B. Riley Wealth Advisors Inc. Sells 2,603 Shares of Haleon plc (NYSE:HLN)

B. Riley Wealth Advisors Inc. decreased its holdings in shares of Haleon plc (NYSE:HLN) by 12.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,498 shares of the company’s stock after selling 2,603 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Haleon were worth $184,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Peapack Gladstone Financial Corp raised its stake in shares of Haleon by 3.2% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after acquiring an additional 1,390 shares in the last quarter. Synovus Financial Corp lifted its stake in shares of Haleon by 0.8% in the third quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after buying an additional 1,216 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Haleon during the 3rd quarter worth $203,000. Sanctuary Advisors LLC grew its stake in Haleon by 25.0% in the 3rd quarter. Sanctuary Advisors LLC now owns 245,310 shares of the company’s stock valued at $2,367,000 after buying an additional 49,064 shares during the last quarter. Finally, Toronto Dominion Bank raised its holdings in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

Shares of Haleon stock opened at $9.69 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market cap of $43.86 billion, a PE ratio of 28.50, a price-to-earnings-growth ratio of 2.95 and a beta of 0.28. The firm has a fifty day moving average price of $9.71 and a two-hundred day moving average price of $9.57. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80.

Analyst Ratings Changes

A number of research firms have issued reports on HLN. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley raised their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.